Evidence outlook
Approved: Multiple Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Relapsing forms of multiple sclerosis (RMS) and early primary progressive MS (PPMS)
- Relapsing-remitting MS (PPMS added Feb 2018)
- Relapsing forms of MS and primary progressive MS
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
WINDOCRE NCT05999604 · Multiple Sclerosis Registry: NCT05999604 | 3 | Absence of radiological disease activity at 2 years (Months24) 2028-05 | In progress: results expected 1 May 2028 | not yet graded | link ↗ |
View 5 more trials
NCT00676715 NCT00676715 · Multiple Sclerosis, Relapsing-Remitting Randomized, double-blind phase 2 in relapsing-remitting multiple sclerosis (220 participants). Both ocrelizumab doses reduced gadolinium-enhancing brain lesions decisively versus placebo (p<0.0001); the endpoint is an MRI biomarker rather than a clinical relapse or disability outcome, which is why the grade is moderate despite the clear result. Registry: NCT00676715 | 2 | Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain (Week 12 to Week 24) 2012-03-09 | Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain (Week 12 to Week 24): Ocrelizumab 600 mg / Ocrelizumab 600 mg 0.6 lesions (Standard Deviation 1.52) | Ocrelizumab 1000 mg/ Ocrelizumab 600 mg 0.2 lesions (Standard Deviation 0.65) vs Placebo / Ocrelizumab 600 mg 5.6 lesions (Standard Deviation 12.53) | Avonex / Ocrelizumab 600 mg 6.9 lesions (Standard Deviation 16.01) | Partial signal | link ↗ |
NCT01194570 NCT01194570 · Multiple Sclerosis Registry: NCT01194570 | 3 | Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period (Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm) 2015-07-23 | 12-week confirmed disability progression: 32.9% with ocrelizumab vs 39.3% with placebo; HR 0.76 (95% CI 0.59-0.98), P=0.03 (ORATORIO, NEJM 2017). | not yet graded | link ↗ |
NCT01247324 NCT01247324 · Relapsing Multiple Sclerosis This was a randomized, triple-blind, active-controlled trial of 821 participants, with ocrelizumab compared against interferon beta-1a. The hard clinical primary endpoint, annualized relapse rate at 96 weeks, was significantly better with ocrelizumab (p<0.0001), supporting a strong evidence grade. Registry: NCT01247324 | 3 | Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96) 2015-04-02 | Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2) | Reliable signal | link ↗ |
NCT03085810 NCT03085810 · Multiple Sclerosis The main study gave ocrelizumab to every participant without randomization, blinding or a comparison group, so its disability outcomes cannot be compared against another treatment. The only randomized part compared two infusion speeds for infusion reactions, which is a safety question and not a test of efficacy. Registry: NCT03085810 | 3 | Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS) (Baseline up to 4 years); Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSS (At Weeks 24 and 48 during Year 1); Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSS (Year 1 (Weeks 24 and 48)); Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSS (At Weeks 48, 72 and 96 during Year 2); Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSS (Year 2 (Weeks 72 and 96)); Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSS (At Weeks 144, 168 and 192 during Year 4); Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSS (Year 4 (Weeks 168 and 192)); Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSS (Year 1 (Week 48)); Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSS (Year 2 (Week 96)); Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSS; Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSS; Mean Change From Baseline in EDSS Score at Week 24 (From Baseline to Week 24); Mean Change From Baseline in EDSS Score at Week 48 (From Baseline to Week 48); Mean Change From Baseline in EDSS Score at Week 72 (From Baseline to Week 72); Mean Change From Baseline in EDSS Score at Week 96 (Baseline, Week 96); Mean Change From Baseline in EDSS Score at Week 120 (Baseline, Week 120); Mean Change From Baseline in EDSS Score at Week 144 (Baseline, Week 144); Mean Change From Baseline in EDSS Score at Week 168 (Baseline, Week 168); Mean Change From Baseline in EDSS Score at Week 192 (Baseline, Week 192); Percentage of Participants Without Protocol-Defined Event of Disease Activity (Baseline up to 4 years); Percentage of Participants Without Relapse (Baseline up to 4 years); Annualized Relapse Rate (Baseline up to 4 years); Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion Substudy (Week 24 through Week 144) 2023-04-27 | Stopped early (terminated). Key figures are not recorded here. | Weak signal | link ↗ |
Operetta 2 NCT05123703 · Multiple Sclerosis This was a randomized, double-blind, double-dummy trial against an active treatment, fingolimod, with relapse rate as the primary outcome. Ocrelizumab met the prespecified non-inferiority test for relapses, a sample size calculation was reported, and 187 patients were randomized against a planned 171. Registry: NCT05123703 | 3 | Protocol-defined Annualized Relapse Rate (ARR) (Up to after the last participant randomized completed 24 weeks since first study treatment administration (up to approximately 160 weeks)) 2025-06-09 | Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (13)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 4 (1)
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other CD20 drugs
Obinutuzumab, Ocrevus Zunovo, Ofatumumab, PF-05280586, Rituximab and 10 more. Compare all 16 CD20 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Multiple Sclerosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ocrelizumab: this drug | Approved | Monoclonal antibody | CD20 | Partial signal | NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk. NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2) | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | Partial signal | NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68) | |
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | not yet graded | No reviewed efficacy summary in this indication | |
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | Reliable signal | NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38) | |
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | not yet graded | No reviewed efficacy summary in this indication | |
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | Reliable signal | NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo. NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012). | |
| Diroximel Fumarate (Vumerity) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | Weak signal | NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. | |
| Fampridine (Ampyra / Fampyra) | Approved | Small molecule | Potassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family) | Partial signal | NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009) | |
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | Reliable signal | NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM). | |
| Interferon Beta-1a (Avonex) | Approved | Biologic (subtype unspecified) | Type I Interferon receptor (IFNAR) | Weak signal | NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year | |
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Partial signal | NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed | |
| Natalizumab (Tysabri) | Approved | Monoclonal antibody | α4 integrin | Reliable signal | NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001). NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63) | |
| Obinutuzumab | Approved(overall) | Monoclonal antibody | CD20 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ocrevus Zunovo | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved | Monoclonal antibody | CD20 | Reliable signal | NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06). | |
| Ozanimod (Zeposia) | Approved | Small molecule | S1P receptor | Partial signal | NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44) | |
| Peginterferon Beta-1a (Plegridy) | Approved | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | Reliable signal | NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037). | |
| PF-05280586 | Approved(overall) | Biologic (subtype unspecified) | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ponesimod | Approved | Small molecule | S1P receptor | Reliable signal | NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. | |
| Rebif (interferon Beta 1a) | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | Weak signal | Featured results are non-efficacy only in this race | |
| Rituximab (Rituxan) | Approved(overall) | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Rituximab-Abbs (Truxima) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Siponimod (Mayzent) | Approved | Small molecule | S1P receptor | Weak signal | NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). | |
| Tascenso ODT | Approved | Small molecule | S1P receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Teriflunomide HMR1726 (Aubagio) | Approved | Small molecule | Dihydroorotate dehydrogenase (DHODH) | Reliable signal | NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction) NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results). | |
| Tyruko (natalizumab-Sztn) | Approved | Monoclonal antibody | α4 integrin | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved | Monoclonal antibody | CD20 | Reliable signal | NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283) | |
| ABP 692 | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Acellbia | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3 | Monoclonal antibody | CD20 | Reliable signal | NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164 | |
| Fenebrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Frexalimab | Phase 3 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | not yet graded | No reviewed efficacy summary in this indication | |
| HLX01 (Hanlikang) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Nabiximols (Sativex) | Phase 3 | Botanical | Cannabinoid CB1/CB2 receptors (agonist) | Partial signal | NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed | |
| Obinutuzumab Beta (Bejescin) | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Remibrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Tolebrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal | NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results). NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed | |
| Vidofludimus Calcium | Phase 3 | — | Dihydroorotate dehydrogenase (DHODH) | not yet graded | No reviewed efficacy summary in this indication | |
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | Partial signal | NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001 | |
| Corubrutinib | Phase 2 | Small molecule | Bruton's tyrosine kinase (BTK) | Partial signal | NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released) | |
| Foralumab | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Irafamdastat | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| A-005 | Phase 1(overall) | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| IDP-023 | Phase 1 | Cell therapy | Allogeneic g-NK cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448501 | Phase 1(overall) | Multispecific antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RG6035 | —(overall) | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6182 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Baminercept | Discontinued | Protein / enzyme therapeutic | Lymphotoxin-beta receptor (LTβR) | not yet graded | No reviewed efficacy summary in this indication | |
| Firategrast (SB-683699) | Discontinued | Small molecule | VLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ocrelizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
2028 (3)
May 2028 (1)
What to watch
2029 (3)
February 2029 (1)
What to watch
August 2029 (1)
What to watch
December 2029 (1)
What to watch
2031 (1)
August 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent